Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

被引：0

作者：

Paolo A Ascierto

Antonio M Grimaldi

Ana Carrizosa Anderson

Carlo Bifulco

Alistair Cochran

Claus Garbe

Alexander M Eggermont

Mark Faries

Soldano Ferrone

Jeffrey E Gershenwald

Thomas F Gajewski

Ruth Halaban

F Stephen Hodi

Richard Kefford

John M Kirkwood

James Larkin

Sancy Leachman

Michele Maio

Richard Marais

Giuseppe Masucci

Ignacio Melero

Giuseppe Palmieri

Igor Puzanov

Antoni Ribas

Yvonne Saenger

Bastian Schilling

Barbara Seliger

David Stroncek

Ryan Sullivan

Alessandro Testori

Ena Wang

Gennaro Ciliberto

Nicola Mozzillo

Francesco M Marincola

Magdalena Thurin

机构：

[1] Istituto Nazionale Tumori,Center for Neurologic Diseases

[2] Fondazione "G.Pascale",Departments of Pathology and Laboratory Medicine and Surgery

[3] Harvard Medical School,Center for Dermato Oncology, Department of Dermatology

[4] Translational Molecular Pathology,Department of Surgery

[5] Earle A. Chiles Research Institute,Department of Surgical Oncology

[6] Providence Cancer Center,Departments of Medicine and of Pathology

[7] David Geffen School of Medicine at University of California Los Angeles (UCLA),Department of Dermatology

[8] John Wayne Cancer Institute,Department of Medical Oncology

[9] University of Tübingen,Division of Hematology/Oncology, Departments of Medicine, Dermatology, and Translational Science

[10] Cancer Institute Gustave Roussy,Department of Dermatology

[11] Donald L. Morton Melanoma Research Program,Medical Oncology and Immunotherapy, Department of Oncology

[12] John Wayne Cancer Institute,Department of Oncology

[13] Massachusetts General Hospital,Pathology

[14] Harvard Medical School,Unit of Cancer Genetics

[15] The University of Texas MD Anderson Cancer Center,Division of Hematology and Oncology, Tisch Cancer Institute, Department of Dermatology

[16] Immunology and Cancer Program,Department of Dermatology

[17] The University of Chicago Medicine,Cell Processing Section, Department of Transfusion Medicine

[18] Yale University School of Medicine,Division Chief of Translational Medicine

[19] Dana-Farber Cancer Institute,undefined

[20] Westmead Institute for Cancer Research,undefined

[21] Westmead Millennium Institute and Melanoma Institute Australia,undefined

[22] University of Sydney,undefined

[23] University of Pittsburgh School of Medicine and Melanoma Program of the Pittsburgh Cancer Institute,undefined

[24] Royal Marsden NHS Foundation Trust,undefined

[25] Oregon Health Sciences University,undefined

[26] University Hospital of Siena,undefined

[27] Istituto Toscano Tumori,undefined

[28] Molecular Oncology Group,undefined

[29] The Paterson Institute for Cancer Research,undefined

[30] The Karolinska Hospital,undefined

[31] Centro de Investigación Médica Aplicada,undefined

[32] Clinica Universidad de Navarra,undefined

[33] Institute of Biomolecular Chemistry,undefined

[34] National Research Council,undefined

[35] Vanderbilt University Medical Center,undefined

[36] Tumor Immunology Program,undefined

[37] Jonsson Comprehensive Cancer Center (JCCC),undefined

[38] David Geffen School of Medicine,undefined

[39] University of California Los Angeles (UCLA),undefined

[40] Icahn School of Medicine at Mount Sinai,undefined

[41] University Hospital,undefined

[42] West German Cancer Center,undefined

[43] University Duisburg-Essen,undefined

[44] Martin Luther University Halle-Wittenberg,undefined

[45] Institute of Medical Immunology,undefined

[46] Clinical Center,undefined

[47] NIH,undefined

[48] Center for Melanoma,undefined

[49] Massachusetts General Hospital Cancer Center,undefined

[50] Harvard Medical School,undefined

来源：

Journal of Translational Medicine | / 12卷

关键词：

Melanoma; Overall Survival; Ipilimumab; Vemurafenib; Chimeric Antigen Receptor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The fourth "Melanoma Bridge Meeting" took place in Naples, December 5 to 8th, 2013. The four topics discussed at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers.

引用

共 1458 条

[1]

Hodi FS(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723

[2]

O'Day SJ(2011)Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2507-2516

[3]

McDermott DF(2001)Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity Cell Signal 13 777-785

[4]

Weber RW(2002)Mutations of the BRAF gene in human cancer Nature 417 949-954

[5]

Sosman JA(2012)Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to thebrain (BREAK-MB): a multicentre, open-label, phase 2 trial Lancet Oncol 13 1087-1095

[6]

Haanen JB(2008)Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc Natl Acad Sci U S A 105 3041-3046

[7]

Gonzalez R(2006)BRAF mutation predicts sensitivity to MEK inhibition Nature 439 358-362

[8]

Robert C(2006)Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma J Invest Dermatol 126 154-160

[9]

Schadendorf D(2012)Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 1694-1703

[10]

Hassel JC(2010)Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 3167-3175

← 1 2 3 4 5 6 7 8 9 10 →